Literature DB >> 14531906

Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities.

Thomas Rasmussen1, Kim Theilgaard-Mönch, Heidi R Hudlebusch, Marianne Lodahl, Hans E Johnsen, Inger Marie S Dahl.   

Abstract

This study investigated the expression pattern in primary plasma cells (PCs) of putative oncogenes suggested to be involved in multiple myeloma (MM) development. cDNA archives were generated by global reverse transcription polymerase chain reaction from CD38++/CD19-/CD56-/++ aberrant PCs of a prospective cohort of 96 subjects, including healthy individuals, patients with monoclonal gammopathies of undetermined significance (MGUS), MM and MM with extramedullary manifestations (ExMM). The cDNA archives were analysed quantitatively for expression of the cyclin D1, fibroblast growth factor receptor 3 (FGFR3), C-MYC, C-MAF and cyclin D3 oncogenes. In addition, all patients were screened for IGH-MMSET hybrid transcripts. None of the analysed oncogenes was randomly distributed. C-MYC and cyclin D3 expression increased at the extramedullary transformation stage. Furthermore, C-MYC and cyclin D3 expression in CD56+ MM was similar to MGUS, whereas CD56- MM was similar to ExMM. FGFR3/IGH-MMSET was only observed among CD56+ MM patients, whereas an increased frequency of C-MAF dysregulation was seen among CD56- MM. High cyclin D1 expression levels were identified at similar frequencies at all stages, whereas the frequency of patients with low cyclin D1 levels increased during MM development. These data support the stepwise transformation model accumulating genetic alterations and proliferative capacity during MM initiation and development resulting in different clinical entities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531906     DOI: 10.1046/j.1365-2141.2003.04577.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

Review 1.  The myeloma stem cell concept, revisited: from phenomenology to operational terms.

Authors:  Hans Erik Johnsen; Martin Bøgsted; Alexander Schmitz; Julie Støve Bødker; Tarec Christoffer El-Galaly; Preben Johansen; Peter Valent; Niklas Zojer; Els Van Valckenborgh; Karin Vanderkerken; Mark van Duin; Pieter Sonneveld; Martin Perez-Andres; Alberto Orfao; Karen Dybkær
Journal:  Haematologica       Date:  2016-11-10       Impact factor: 9.941

2.  Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.

Authors:  Thomas Rasmussen; Jacob Haaber; Inger Marie Dahl; Lene M Knudsen; Gitte B Kerndrup; Marianne Lodahl; Hans E Johnsen; Michael Kuehl
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

3.  Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.

Authors:  Naohiro Sekiguchi; Kaori Ootsubo; Miyuki Wagatsuma; Kiyoe Midorikawa; Akihisa Nagata; Satoshi Noto; Kazuaki Yamada; Naoki Takezako
Journal:  Int J Hematol       Date:  2014-02-05       Impact factor: 2.490

4.  A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Authors:  Julie Støve Bødker; Rasmus Froberg Brøndum; Alexander Schmitz; Anna Amanda Schönherz; Ditte Starberg Jespersen; Mads Sønderkær; Charles Vesteghem; Hanne Due; Caroline Holm Nørgaard; Martin Perez-Andres; Mehmet Kemal Samur; Faith Davies; Brian Walker; Charlotte Pawlyn; Martin Kaiser; David Johnson; Uta Bertsch; Annemiek Broyl; Mark van Duin; Rajen Shah; Preben Johansen; Martin Agge Nørgaard; Richard J Samworth; Pieter Sonneveld; Hartmut Goldschmidt; Gareth J Morgan; Alberto Orfao; Nikhil Munshi; Hans Erik Johnson; Tarec El-Galaly; Karen Dybkær; Martin Bøgsted
Journal:  Blood Adv       Date:  2018-09-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.